Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline 0.9% Clear all
Recruiting Phase 1 Interventional

Metabolic Effects of Angiotensin-(1-7)

NCT02646475
View directory record Official record
Conditions
Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 3 Interventional

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

NCT04636229
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Amniotic Suspension Allograft, Placebo
Biological · Drug
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

NCT06112353
View directory record Official record
Conditions
Intestinal Disease
Interventions
Neostigmine Injectable Solution, Sugammadex injection
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 25, 2026, 11:43 PM EDT
Not listed Not applicable Interventional

Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning

NCT06418022
View directory record Official record
Conditions
Shock, Fluid Overload, Cardiac Output, Low
Interventions
Trendelenburg positioning VTI
Device
Lead sponsor
Lenox Hill Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 11:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition

NCT02227329
View directory record Official record
Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
Interventions
Ethanol, Heparin Lock, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 25, 2026, 11:43 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache

NCT03472872
View directory record Official record
Conditions
Headache
Interventions
Ketorolac, Acetaminophen
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Fluzone HD
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
34
States / cities
Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 25, 2026, 11:43 PM EDT
Not listed Phase 4 Interventional

Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19

NCT04603794
View directory record Official record
Conditions
COVID-19
Interventions
0.5% Povidone Iodine, 0.12% Chlorhexidine Gluconate Mouth Rinse, 1% Hydrogen Peroxide, 0.9% Normal Saline
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 25, 2026, 11:43 PM EDT
Recruiting Phase 3 Interventional

Saline Versus Balanced Crystalloid in Traumatic Brain Injury

NCT06953674
View directory record Official record
Conditions
Traumatic Brain Injury (TBI) Patients
Interventions
Normal Saline (0.9% NaCl), balanced crystalloid
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

NCT03070782
View directory record Official record
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)

NCT03063476
View directory record Official record
Conditions
Healthy
Interventions
C-13 labeled Lysine, Normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 25, 2026, 11:43 PM EDT
Withdrawn Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 11:43 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Not applicable Interventional Results available

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

NCT01608308
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 68 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 25, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 25, 2026, 11:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

NCT02985879
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Placebo, ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 25, 2026, 11:43 PM EDT
Recruiting Phase 4 Interventional

Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment

NCT06085183
View directory record Official record
Conditions
Ureter Injury
Interventions
Saline Injection 0.9%, Indigotindisulfonate sodium 0.8%
Other · Drug
Lead sponsor
Prove pharm
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 11:43 PM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 25, 2026, 11:43 PM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Early Phase 1 Interventional

IV Tranexamic Acid Prior to Hysterectomy

NCT02911831
View directory record Official record
Conditions
Hysterectomy, Blood Loss, Surgical
Interventions
Tranexamic Acid, Sodium Chloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 25, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

NCT02609789
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy
Interventions
JNJ-55920839, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 11:43 PM EDT
Recruiting Early Phase 1 Interventional

Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds

NCT05169814
View directory record Official record
Conditions
Open Wound, Wound Heal
Interventions
Micro/nanobubble (MNB) - Irrigation, 0.9% Normal Saline - Irrigation, Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi), 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 25, 2026, 11:43 PM EDT
Active, not recruiting Phase 3 Interventional

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 11:43 PM EDT